Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 274

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 274
---
. Subsequently, on April 24, 2023, Mr. Calmet shared with Mr. Bransfield notes of the MultiplAI meeting, which were later discussed in a call that same day. During that call, the possibility of adding an additional deal with MultiplAI for a business combination transaction was explored. MultiplAI is unrelated to, and shares no common ownership with, the Parent, the Sponsor, the Initial Sponsor, Theo, Union Acquisition Group, Heritas or Bioceres. After the call, representatives of MultiplAI and OmnigenicsAI began sharing information on products, financials, organizational and legal documents to conduct a high -levelbusiness due diligence, in parallel to the drafting of an LOI. On May 9, 2023, Mr. Calmet introduced Mr. Ramondt to Mr. Bransfield during a three -waycall. During this call, the parties discussed the possibility of a business combination transaction that would include OmnigenicsAI merging with a SPAC and acquiring MultiplAI with the use of proceeds of the de -SPACtransaction. The parties also discussed potential ideas as to what the Combined Company would look like from a strategic point of view. On May 18, 2023, Union Acquisition Group shared a first draft of a letter of intent with OmnigenicsAI that detailed the terms and conditions of an acquisition of OmnigenicsAI by Templar LLC, a Tennessee limited liability company controlled by Mr. Bransfield (the “Sponsor”), who had the mandate to purchase a SPAC for the transaction (the “Heritas LOI”). Upon Mr. Bransfield’s relocation to Nashville, TN, he determined that Sponsor was the appropriate vehicle to act as the Sponsor for the present transaction. Union Acquisition Group did not receive any compensation for its services prior to the involvement of Sponsor. The Heritas LOI draft contained the following material provisions: •a target enterprise valuation of $300,000,000 for OmnigenicsAI (which was proposed following an analysis of a wide variety of comparable companies, as described more fully below, taking into account OmnigenicAI’s relatively lower cash burn rates, its unique product offering, its total addressable market and its ability to commercialize and scale within the geographics in which it operates; no fairness opinion or other third party analysis was performed, and no detailed projections were prepared in arriving at such figure); •Sponsor (through a special purpose acquisition company) would acquire 100% of the